Johnson & JohnsonJNJ
Makes prescription medicines, including cancer and immunology drugs, and medical devices for surgery, orthopaedics and heart care.
Share price
Key figures, last 12 months
- Market cap
- $665.0bn at 276.25, 6 November 2026
- Revenue growth
- +7.8% on $99.3bn of revenue
- Operating margin
- —
- Free cash flow margin
- 20.7% −0.5 pts on a year earlier
- ROIC
- —
Financial metrics
- Revenue
- $99.3bn +7.8% on a year earlier
- Net income
- $16.1bn −35.9% on a year earlier
- Earnings per share
- $6.57
- Price to earnings
- 42.0×
- Free cash flow
- $20.6bn +5.1% on a year earlier
- Profit turned into cash
- 127.9%
- Spending on build-out
- 5.6% +0.6 pts on a year earlier
- Cash and investments
- $17.2bn
- Total debt
- $44.7bn
- Net cash
- −$27.4bn
- Debt to equity
- 0.55×
- Shares (diluted)
- 2.45bn +0.8% on a year earlier
Revenue by financial year
Latest filings
- Quarterly report to 27 September 202621 October 2026
- Quarterly report to 28 June 202623 July 2026
- Quarterly report to 29 March 202622 April 2026
Coming soon
Hindsight Analysis
A closer look at Johnson & Johnson’s finances: what the figures reveal, the risks they show, and how the company’s promises compare with its results.
Charts and live prices are delayed, from TradingView. Market values use each company’s last trade on IEX at the previous close, times the shares in issue from its filings; company figures come from SEC filings. This is information, not investment advice. Where our market data comes from
Company logos are trademarks of their owners, shown only to identify them; the files are from Wikimedia Commons.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.